263 related articles for article (PubMed ID: 33461835)
1. The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL).
Whitaker JA; Parikh SA; Shanafelt TD; Kay NE; Kennedy RB; Grill DE; Goergen KM; Call TG; Kendarian SS; Ding W; Poland GA
Vaccine; 2021 Feb; 39(7):1122-1130. PubMed ID: 33461835
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with humoral immune response in older adults who received egg-free influenza vaccine.
Williams KV; Moehling Geffel K; Alcorn JF; Patricia Nowalk M; Levine MZ; Kim SS; Flannery B; Susick M; Zimmerman RK
Vaccine; 2023 Jan; 41(3):862-869. PubMed ID: 36543682
[TBL] [Abstract][Full Text] [Related]
3. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.
Muchtar E; Koehler AB; Johnson MJ; Rabe KG; Ding W; Call TG; Leis JF; Kenderian SS; Hayman SR; Wang Y; Hampel PJ; Holets MA; Darby HC; Slager SL; Kay NE; Miao C; Canniff J; Whitaker JA; Levin MJ; Schmid DS; Kennedy RB; Weinberg A; Parikh SA
Am J Hematol; 2022 Jan; 97(1):90-98. PubMed ID: 34699616
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
Gorse GJ; Grimes S; Buck H; Mulla H; White P; Hill H; May J; Frey SE; Blackburn P
Vaccine; 2022 Feb; 40(9):1271-1281. PubMed ID: 35125219
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of seasonal inactivated influenza and inactivated polio vaccines among children in Senegal: Results from a cluster-randomized trial.
Niang M; Deming ME; Goudiaby D; Diop OM; Dia N; Diallo A; Ortiz JR; Diop D; Lewis KDC; Lafond KE; Widdowson MA; Victor JC; Neuzil KM
Vaccine; 2020 Nov; 38(47):7526-7532. PubMed ID: 33012603
[TBL] [Abstract][Full Text] [Related]
7. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
[TBL] [Abstract][Full Text] [Related]
8. Does prior vaccination affect the immune response to seasonal influenza vaccination among older adults? Findings from a prospective cohort study in a Northeastern Province of Thailand.
Praphasiri P; Prasert K; Shrestha M; Ditsungnoen D; Chittaganpich M; Chawalchitiporn S; Dawood FS; Sirilak S; Mott JA
PLoS One; 2023; 18(2):e0279962. PubMed ID: 36735691
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017-2018.
Belongia EA; Levine MZ; Olaiya O; Gross FL; King JP; Flannery B; McLean HQ
Vaccine; 2020 Mar; 38(15):3121-3128. PubMed ID: 32145994
[TBL] [Abstract][Full Text] [Related]
11. Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine.
Shinde V; Cai R; Plested J; Cho I; Fiske J; Pham X; Zhu M; Cloney-Clark S; Wang N; Zhou H; Zhou B; Patel N; Massare MJ; Fix A; Spindler M; Thomas DN; Smith G; Fries L; Glenn GM
Clin Infect Dis; 2021 Dec; 73(11):e4278-e4287. PubMed ID: 33146720
[TBL] [Abstract][Full Text] [Related]
12. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain.
Hung IF; Levin Y; To KK; Chan KH; Zhang AJ; Li P; Li C; Xu T; Wong TY; Yuen KY
Vaccine; 2012 Oct; 30(45):6427-35. PubMed ID: 22910287
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
[TBL] [Abstract][Full Text] [Related]
14. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
Narang V; Lu Y; Tan C; Camous XFN; Nyunt SZ; Carre C; Mok EWH; Wong G; Maurer-Stroh S; Abel B; Burdin N; Poidinger M; Tambyah PA; Bosco N; Visan L; Ng TP; Larbi A
Front Immunol; 2018; 9():2465. PubMed ID: 30405641
[No Abstract] [Full Text] [Related]
15. Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: A pilot randomized clinical trial.
Jamshed S; Walsh EE; Dimitroff LJ; Santelli JS; Falsey AR
Vaccine; 2016 Jan; 34(5):630-635. PubMed ID: 26721330
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial.
Chang LJ; Anderson EJ; Jeanfreau R; He Y; Hicks B; Shrestha A; Pandey A; Landolfi V; DeBruijn I;
Vaccine; 2021 Mar; 39(11):1572-1582. PubMed ID: 33610374
[TBL] [Abstract][Full Text] [Related]
17. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
18. Nine μg intradermal influenza vaccine and 15 μg intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults.
Nougarede N; Bisceglia H; Rozières A; Goujon C; Boudet F; Laurent P; Vanbervliet B; Rodet K; Hennino A; Nicolas JF
Hum Vaccin Immunother; 2014; 10(9):2713-20. PubMed ID: 25483667
[TBL] [Abstract][Full Text] [Related]
19. Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies.
Héquet D; Pascual M; Lartey S; Pathirana RD; Bredholt G; Hoschler K; Hullin R; Meylan P; Cox RJ; Manuel O
Vaccine; 2016 Jun; 34(31):3576-83. PubMed ID: 27219339
[TBL] [Abstract][Full Text] [Related]
20. The safety and immunogenicity of trivalent inactivated influenza vaccination: a study of maternal-cord blood pairs in Taiwan.
Lin SY; Wu ET; Lin CH; Shyu MK; Lee CN
PLoS One; 2013; 8(6):e62983. PubMed ID: 23762229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
